Table 4.
Value distribution of VEGF in various response groups of NSCLC patients during first-line chemotherapy
| P | |||||
|---|---|---|---|---|---|
| Biomarkers (unit) | Remission median (range) | No Change median (range) | Progression median (range) | R+NC vs P | R vs NC+P |
| VEGF BV1 (pg/mL) | 364.0 (136.6-868.0) | 180.5 (70.6-546.0) | 286.4 (72.6-522.6) | 0.589 | 0.083 |
| VEGF BV2 (pg/mL) | 144.0 (34.6-588.4) | 237.8 (52.1-431.0) | 325.2 (158.4-612.1) | 0.001 | 0.016 |
| VEGF BV3 (pg/mL) | 119.0 (26.0-571.0) | 269.7 (51.0-526.0) | 402.8 (174.6-811.0) | 0.001 | 0.001 |
| VEGF BV1-2 (Dec%) | 41.6 (2.2-86.8) | -6.6 (-90.6-64.5) | -18.5 (-118.2-2.7) | 0.0001 | 0.0001 |
| VEGF BV1-3 (Dec%) | 63.0 (17.2-93.1) | -3.2 (-142.2-53.0) | -41.0 (-140.5- -17.8) | 0.0001 | 0.0001 |
| VEGF BV2-3 (Dec%) | 12.7 (-62.4-87.1) | -21.2 (-33.6-33.8) | -15.3 (-66.3-5.3) | 0.0268 | 0.0052 |
BV1, BV2, and BV3, baseline VEGF levels before therapy cycle 1 to 3, respectively; BV1-2, BV1-3 and BV2-3, kinetics of baseline VEGF levels from cycles 1 to 2, 1 to 3 and 2 to 3, respectively; Dec%, decrease in percent (negative numbers meaning increase of the VEGF levels). P values by Wilcoxon test indicate differences between patients with progressive disease (P) and those having remission and stable disease (R+NC; evaluation 1) as well as between patients with remission (R) and those having progressive and stable disease (P+NC; evaluation 2).